Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The latest announcement is out from Tianda Pharmaceuticals Ltd. ( (HK:0455) ).
Tianda Pharmaceuticals Limited has scheduled a board meeting for 26 March 2026 to review and approve the audited final results for the financial year ended 31 December 2025. The board will also consider the declaration of a final dividend, a decision that could directly affect shareholder returns and signal management’s confidence in the company’s financial performance and outlook.
The announcement also confirms the current composition of the company’s board, comprising executive, non executive and independent non executive directors. This governance structure reflects established oversight practices in Hong Kong’s listed pharmaceutical sector and provides continuity as the company prepares to release its annual results and potentially adjust its capital return policy.
The most recent analyst rating on (HK:0455) stock is a Hold with a HK$0.10 price target. To see the full list of analyst forecasts on Tianda Pharmaceuticals Ltd. stock, see the HK:0455 Stock Forecast page.
More about Tianda Pharmaceuticals Ltd.
Tianda Pharmaceuticals Limited is a Hong Kong listed pharmaceutical company focused on the development, manufacture and sale of pharmaceutical products. The group operates through its subsidiaries and is active in the broader healthcare sector, serving markets that rely on both traditional and modern medical therapies.
Average Trading Volume: 126,645
Technical Sentiment Signal: Strong Sell
Current Market Cap: HK$208.6M
See more data about 0455 stock on TipRanks’ Stock Analysis page.